Geode Capital Management
NGNE icon

Geode Capital Management’s Neurogene NGNE Stock Holding History

Geode Capital Management’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.63M Buy
279,003
+29,308
+12% +$568K ﹤0.01% 2678
2025
Q4 		$5.14M Buy
249,695
+3,262
+1% +$81.2K ﹤0.01% 2751
2025
Q3 		$4.27M Sell
246,433
-1,342
-0.5% -$27K ﹤0.01% 2865
2025
Q2 		$3.7M Sell
247,775
-11,601
-4% -$182K ﹤0.01% 2885
2025
Q1 		$3.04M Buy
259,376
+24,751
+11% +$430K ﹤0.01% 2884
2024
Q4 		$5.36M Buy
234,625
+14,026
+6% +$522K ﹤0.01% 2716
2024
Q3 		$9.26M Sell
220,599
-1,463
-0.7% -$56.7K ﹤0.01% 2428
2024
Q2 		$8.08M Buy
222,062
+122,748
+124% +$4.33M ﹤0.01% 2460
2024
Q1 		$5.06M Buy
99,314
+83,595
+532% +$2.79M ﹤0.01% 2700
2023
Q4 		$305K Sell
15,719
-2
-0% -$29 ﹤0.01% 3792
2023
Q3 		$248K Buy
15,721
+668
+4% +$9.86K ﹤0.01% 3894
2023
Q2 		$250K Hold
15,053
– – ﹤0.01% 3942
2023
Q1 		$211K Hold
15,053
– – ﹤0.01% 4024
2022
Q4 		$153K Sell
15,053
-36
-0.2% -$372 ﹤0.01% 4223
2022
Q3 		$193K Hold
15,089
– – ﹤0.01% 4235
2022
Q2 		$310K Sell
15,089
-14,236
-49% -$347K ﹤0.01% 4014
2022
Q1 		$1.1M Sell
29,325
-82
-0.3% -$4.78K ﹤0.01% 3575
2021
Q4 		$2.83M Sell
29,407
-1,484
-5% -$181K ﹤0.01% 3195
2021
Q3 		$4.47M Buy
30,891
+1,760
+6% +$269K ﹤0.01% 2969
2021
Q2 		$5.38M Buy
29,131
+2,269
+8% +$502K ﹤0.01% 2852
2021
Q1 		$6.61M Buy
26,862
+3,097
+13% +$792K ﹤0.01% 2641
2020
Q4 		$6.7M Buy
23,765
+1,562
+7% +$382K ﹤0.01% 2421
2020
Q3 		$5.33M Buy
22,203
+379
+2% +$91.8K ﹤0.01% 2358
2020
Q2 		$7.25M Buy
21,824
+7,279
+50% +$1.9M ﹤0.01% 2117
2020
Q1 		$3.31M Buy
14,545
+935
+7% +$192K ﹤0.01% 2387
2019
Q4 		$3.35M Buy
13,610
+5,079
+60% +$506K ﹤0.01% 2694
2019
Q3 		$486K Sell
8,531
-5
-0.1% -$305 ﹤0.01% 3480
2019
Q2 		$402K Buy
8,536
+3
+0% +$154 ﹤0.01% 3545
2019
Q1 		$459K Buy
8,533
+9
+0.1% +$455 ﹤0.01% 3465
2018
Q4 		$368K Buy
8,524
+214
+3% +$10.4K ﹤0.01% 3478
2018
Q3 		$486K Hold
8,310
– – ﹤0.01% 3471
2018
Q2 		$440K Buy
8,310
+1,090
+15% +$284K ﹤0.01% 3487
2018
Q1 		$2.03M Buy
7,220
+1,166
+19% +$322K ﹤0.01% 2749
2017
Q4 		$1.42M Sell
6,054
-57
-0.9% -$13.4K ﹤0.01% 2948
2017
Q3 		$1.73M Hold
6,111
– – ﹤0.01% 2833
2017
Q2 		$1.72M Buy
6,111
+34
+0.6% +$9.73K ﹤0.01% 2819
2017
Q1 		$2.03M Buy
6,077
+552
+10% +$194K ﹤0.01% 2664
2016
Q4 		$1.82M Buy
5,525
+1,349
+32% +$363K ﹤0.01% 2681
2016
Q3 		$1.11M Buy
4,176
+1,029
+33% +$207K ﹤0.01% 2881
2016
Q2 		$416K Hold
3,147
– – ﹤0.01% 3291
2016
Q1 		$555 Buy
3,147
+563
+22% +$109K ﹤0.01% 3173
2015
Q4 		$644K Buy
2,584
+229
+10% +$60.3K ﹤0.01% 3146
2015
Q3 		$662K Buy
2,355
+1,549
+192% +$357K ﹤0.01% 3090
2015
Q2 		$111K Hold
806
– – ﹤0.01% 3751
2015
Q1 		$138K Hold
806
– – ﹤0.01% 3681
2014
Q4 		$120K Hold
806
– – ﹤0.01% 3744
2014
Q3 		$107K Buy
+806
New +$123K ﹤0.01% 3738

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Geode Capital Management's NGNE Position: Q1 2026 in Review

Geode Capital Management increased its Neurogene (NGNE) stake by 12% in Q1 2026, buying an estimated $568K and bringing the position to 279,003 shares worth $5.63M. The position accounts for ﹤0.01% of the portfolio, ranked #2678.

Geode Capital Management first reported a position in NGNE in Q3 2014 and has held it in 47 quarters since. The position peaked at $9.26M in Q3 2024. 96 funds tracked by Wall St. Rank hold NGNE as of Q1 2026.

  • Geode Capital Management held 279,003 shares of Neurogene worth $5.63M as of Q1 2026.
  • Geode Capital Management bought 29,308 Neurogene shares in Q1 2026, an estimated $568K.
  • Neurogene made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #2678 holding.
  • Geode Capital Management first reported a position in Neurogene in Q3 2014 and has held it in 47 quarters since.
  • Geode Capital Management's Neurogene position peaked at $9.26M in Q3 2024.
  • 96 funds tracked by Wall St. Rank held Neurogene as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.